1. United States Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Verici Dx Plc

Verici Dx Plc

LLSE:VRCI
0.23
GBX
+0.00
(-2.17%)
1.10BMarket Cap
Jul 05Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.01
- -
- -
Basic EPS, GAAP
- -
-0.06
-0.07
-0.05
-0.03
-0.01
- -
Free Cash Flow per Basic Share
- -
-0.05
-0.07
-0.04
-0.03
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.14
0.08
0.07
0.02
0.02
- -
- -
Tangible Book Value per Share
0.13
0.07
0.06
0.01
0.01
- -
- -
Basic Weighted Avg Shares
87
142
165
170
233
798
878
Sales/Revenue/Turnover
- -
- -
- -
1
3
4
- -
Operating Margin (%)
- -
- -
- -
-875.32
-182.87
-190.28
- -
Depreciation Expense
- -
- -
1
1
1
1
- -
Net Income, GAAP
- -
-8
-11
-9
-6
-7
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-862.19
-175.92
-189.22
- -
Working Capital
17
9
8
- -
3
4
4
LT Debt
- -
- -
1
- -
- -
- -
- -
Total Equity
20
12
12
4
5
7
7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-52.7
-97.11
-115.94
-133.15
-117.81
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
243
1,513
Market Capitalization
12
4
15

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
5
2
5
Cash, Cash Equivalents & STI
4
- -
3
Accounts Receivable, Net
- -
1
1
Inventories
- -
- -
- -
Total Current Liabilities
2
2
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-8.09%
23.55%
Free Cash Flow
- -
- -
36.07%
Net Income, GAAP
- -
- -
18.03%
Sales/Revenue/Turnover
- -
- -
9.73%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
3
2025
- -
- -
4

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.05
2024
- -
- -
-0.03
2025
- -
- -
-0.01

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sara Jane Barrington
Full Time Employees
19
Sector
Health services
Industry
Medical/Nursing services
Address
Avon House Franklin TN United States CF64 2EZ
IPO Date
Nov 3, 2020
Website
vericidx.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Verici Dx plc operates as an immuno-diagnostics innovator, concentrating its efforts within the kidney transplantation field. The company is actively developing advanced prognostic and diagnostic solutions for individuals undergoing kidney transplants. Its product pipeline includes Clarava, a pre-transplant test designed to predict the likelihood of early acute rejection; Tuteva, a post-transplant diagnostic focusing on acute cellular rejection, including sub-clinical forms; and Protega, a liquid biopsy aimed at foreseeing the risk of fibrosis and eventual graft failure. Leveraging AI-enhanced RNA signature analysis, Verici Dx strives to deliver personalized, data-driven insights to clinicians. Established in 2020, the firm maintains its base in Penarth, United Kingdom.